AUTHORS
Heta Patel, MD, Fatma Betul Yilmaz, MD2, Sandra Susanibar-Adaniya, MD, MS3, Alfred L. Garfall, MD4, Dan T. Vogl, MD, MSCE5, Shivani Kapur, MD6, Adam Waxman, MD, MS7, Danielle Zubka, RN8, Wei-Ting Hwang, PhD9, Cynthia Diaczynsky10, Matthew Ho, MBBS, PhD11, Luca Paruzzo, MD12, Marco Ruella, MD13, Joseph Fraietta, PhD14, Edward A. Stadtmauer, MD15, Adam D. Cohen, MD16
AFFILIATIONS
1 University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 University of Pennsylvania, Philadelphia, Pennsylvania, United States
6 University of Pennsylvania, Philadelphia, Pennsylvania, United States
7 University of Pennsylvania, Philadelphia, Pennsylvania, United States
8 University of Pennsylvania, Philadelphia, Pennsylvania, United States
9 University of Pennsylvania, Philadelphia, Pennsylvania, United States
10 University of Pennsylvania, Philadelphia, Pennsylvania, United States
11 University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
12 University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
13 University of Pennsylvania, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
14 University of Pennsylvania, Philadelphia, Pennsylvania, United States
15 University of Pennsylvania, Philadelphia, Pennsylvania, United States
16 University of Pennsylvania, Philadelphia, Pennsylvania, United States
ABSTRACT
Background: We conducted a phase 2 trial (NCT05801939) of cevostamab (cevo, FcRH5xCD3 bispecific antibody) consolidation following BCMA-directed CAR T-cell therapy (CART) for relapsed/refractory multiple myeloma (MM), with promising initial safety and efficacy (Cohen et al, ASH 2025, #699). We sought to investigate the effects of these sequential T-cell engaging therapies on immunoparesis, infection risk, and immune reconstitution.
Methods: We enrolled 27 patients (pts) (25 cilta-cel, 2 ide-cel) from 7/2023-6/2025 (median follow-up 24 months (mos)). Pts received 8 cycles of cevo (160mg IV every (q) 3 weeks (wks)) starting 10-12 wks post-CART. Pts without MRD-negative CR (n=3) received another 8 cycles. We analyzed immune recovery in cevo pts as well as in a retrospectively identified control group (n=29) who received CART (25 cilta-cel, 4 ide-cel) during the same timeframe, met trial eligibility, but did not enroll. Cell count, immunoglobulin, and serum free light chain (SFLC) kinetics were analyzed longitudinally from month 0 (M0) [10-12 weeks post-CART] until progression, death, or data cutoff (6/26/26). Serial T and B-cell counts and CMV/EBV testing (q3mos) were only available for cevo pts. Infection details via chart review included infections occurring beyond the trial-mandated reporting period. All pts received IVIG and PJP prophylaxis.
Results: Pt characteristics were similar except for median age (cevo 64 [33-80], control 69 [63-75]; p=0.013) and sex (cevo 20M, control 14M; p=0.06). Pre-lymphodepletion (pre-LD) absolute lymphocyte counts (ALC), T-cell counts, and CAR-HEMATOTOX scores were not significantly different. Pre-LD absolute neutrophil counts (ANC) were lower in the cevo group (median 2.5 vs 3.2 x 109/L; p=0.02), with similar levels at M0. Cevo pts had lower ANC compared to control pts from M3-M12 (all p<0.01), with GCSF use in 48% vs 2.5% in controls, with no differences from M15-M24. A higher proportion of cevo vs control pts had ALC<0.5x109/L at M6 (60% vs 29%; p=0.03) without significant differences at other timepoints. T-cell counts nadired at M3 (median CD4 97/μl [IQR 56-184], CD8 147/μl [IQR 47-552]) with gradual recovery over time; 35% (9/26) of cevo pts had CD4>200 at M12. Median CD4:CD8 ratios increased from 0.6 (M0) to 0.9 (M12). B cell counts were low at M0 (33% of cevo pts had detectable CD19+ cells (>10/μl); 7% had >100/μl), nadired at M3 (13% and 0%, respectively), and improved but remained suppressed at M12 (50% and 29%, respectively).
Baseline immunoparesis was common with undetectable IgM and uninvolved SFLC (UFLC) levels at M0 in all but 1 cevo and in all control pts. IgM recovery was delayed in the cevo cohort, with significantly lower IgM levels at M3, M6, and M9 (all p<0.01), though median time to IgM normalization was similar between groups (14.8 vs 15.7 mos; p=0.96). Likewise, cevo pts had lower UFLC levels from M3 to M12 (M3; p=0.002, M9; p=0.02) but comparable median time to UFLC normalization (13.6 vs 18.8 mos; p=0.61). Interestingly, 15/27 (56%) cevo pts developed 1 or more non-MM-related paraproteins on SPEP and/or serum immunofixation (ie oligoclonal reconstitution) at a median of 9.4 mos (IQR 8.2-12.4) from M0, with 5 developing quantifiable M-proteins from 0.3-1.6 g/dL. In most pts, these persisted for >6 mos before resolving. Oligoclonal bands were seen in 5/29 (17%) control pts, typically low-level and short-lived.
Cevo was associated with a higher infection incidence (5.6 vs 3.4 per 1000 person-days, IRR 1.64 [95% CI 1.21-2.24]; p=0.0016). Nearly all pts had ≥1 infection with a median of 3 vs 2 infections/pt in the cevo and control group, respectively. Upper respiratory viral infections and pneumonia were most common. Cevo-treated pts had more infections requiring urgent evaluation (IRR 4.17, 95% CI 1.32–20; p=0.028), but rates of serious infections requiring hospitalization were comparable (IRR 1.15, 95% CI 0.42–3.13; p=0.79). Transient low-level CMV was detected in 7 (26%) cevo pts (2 at baseline); all resolved without therapy. No EBV reactivation was observed.
Conclusions: In this exploratory post-hoc analysis, cevo consolidation following CART delayed humoral immune recovery and increased non-severe infections without increasing infections requiring hospitalization. Despite this, cevo promoted more robust humoral immune reconstitution with higher rates of oligoclonal immunoglobulin recovery, a finding associated with improved prognosis in other settings.
DISCLOSURES
Heta Patel, MD: No relevant conflicts of interest to declare.